Harold Bernstein, President, R&D and CMO of Maze Therapeutics ($MAZE), sold shares on the open market eleven times over the past year, totaling $5.2 million. His most recent sale occurred on March 10, 2026. These sales rank 1,868th among 11,678 individual insiders, below the average of $8.6 million per seller and 6.4 transactions. Bernstein made no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Common Stock | 15000 | $10.42 | 15,000.0000 | 48,119,444 | 9999.99% | 0.03% |
| April 1, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Stock Option (Right to Buy) | 15000 | $0.00 | 237,407.0000 | 48,119,444 | 5.94% | 0.03% |
| April 1, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 300 | $31.07 | 0.0000 | 48,119,444 | 100.00% | 0.00% |
| April 1, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 3348 | $30.06 | 300.0000 | 48,119,444 | 91.78% | 0.01% |
| April 1, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 11352 | $29.24 | 3,648.0000 | 48,119,444 | 75.68% | 0.02% |
| March 20, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Common Stock | 15000 | $10.42 | 15,000.0000 | 48,119,444 | 9999.99% | 0.03% |
| March 20, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 6161 | $48.20 | 8,839.0000 | 48,119,444 | 41.07% | 0.01% |
| March 20, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 3795 | $49.32 | 5,044.0000 | 48,119,444 | 42.93% | 0.01% |
| March 20, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 5044 | $50.02 | 0.0000 | 48,119,444 | 100.00% | 0.01% |
| March 20, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Stock Option (Right to Buy) | 15000 | $0.00 | 252,407.0000 | 48,119,444 | 5.61% | 0.03% |
| March 10, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Stock Option (Right to Buy) | 30000 | $0.00 | 267,407.0000 | 48,119,444 | 10.09% | 0.06% |
| March 10, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 348 | $51.02 | 0.0000 | 48,119,444 | 100.00% | 0.00% |
| March 10, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 29652 | $50.45 | 348.0000 | 48,119,444 | 98.84% | 0.06% |
| March 10, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Common Stock | 30000 | $10.42 | 30,000.0000 | 48,119,444 | 9999.99% | 0.06% |
| March 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | A | Stock Option (Right to Buy) | 48000 | $0.00 | 48,000.0000 | 48,119,444 | 9999.99% | 0.10% |
| March 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | A | Restricted Stock Units | 24000 | $0.00 | 24,000.0000 | 48,119,444 | 9999.99% | 0.05% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 8364 | $45.89 | 6,036.0000 | 48,119,444 | 58.08% | 0.02% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 100 | $47.23 | 0.0000 | 48,119,444 | 100.00% | 0.00% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Stock Option (Right to Buy) | 15000 | $0.00 | 297,407.0000 | 48,119,444 | 4.80% | 0.03% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Common Stock | 15000 | $10.42 | 15,000.0000 | 48,119,444 | 9999.99% | 0.03% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 600 | $44.21 | 14,400.0000 | 48,119,444 | 4.00% | 0.00% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 5936 | $46.37 | 100.0000 | 48,119,444 | 98.34% | 0.01% |
| Jan. 7, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Stock Option (Right to Buy) | 25156 | $0.00 | 312,407.0000 | 48,119,444 | 7.45% | 0.05% |
| Jan. 7, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Common Stock | 25156 | $10.42 | 25,156.0000 | 48,119,444 | 9999.99% | 0.05% |
| Jan. 7, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 25156 | $40.20 | 0.0000 | 48,119,444 | 100.00% | 0.05% |
| Jan. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Common Stock | 4432 | $10.42 | 4,432.0000 | 48,119,444 | 9999.99% | 0.01% |
| Jan. 5, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Stock Option (Right to Buy) | 412 | $0.00 | 337,563.0000 | 48,119,444 | 0.12% | 0.00% |
| Jan. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Stock Option (Right to Buy) | 4432 | $0.00 | 337,975.0000 | 48,119,444 | 1.29% | 0.01% |
| Jan. 5, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 412 | $40.00 | 0.0000 | 48,119,444 | 100.00% | 0.00% |
| Jan. 5, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Common Stock | 412 | $10.42 | 412.0000 | 48,119,444 | 9999.99% | 0.00% |
| Jan. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 4432 | $40.43 | 0.0000 | 48,119,444 | 100.00% | 0.01% |
| Dec. 29, 2025 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Common Stock | 45000 | $10.42 | 45,000.0000 | 48,119,444 | 9999.99% | 0.09% |
| Dec. 29, 2025 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | M | Stock Option (Right to Buy) | 45000 | $0.00 | 342,407.0000 | 48,119,444 | 11.62% | 0.09% |
| Dec. 29, 2025 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 17200 | $40.93 | 0.0000 | 48,119,444 | 100.00% | 0.04% |
| Dec. 29, 2025 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | S | Common Stock | 27800 | $40.34 | 17,200.0000 | 48,119,444 | 61.78% | 0.06% |
| Sept. 22, 2025 | Maze Therapeutics, Inc. | $MAZE | Bernstein Harold | President, R&D & CMO | A | Restricted Stock Units | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |